DOCSLIB.ORG

MISSISSIPPI LEGISLATURE REGULAR SESSION 2021 By: Senator(S) Jordan, Jackson (11Th), Thomas SENATE BILL NO. 2278 an ACT TO

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MISSISSIPPI LEGISLATURE REGULAR SESSION 2021 By: Senator(S) Jordan, Jackson (11Th), Thomas SENATE BILL NO. 2278 an ACT TO MISSISSIPPI LEGISLATURE REGULAR SESSION 2021 By: Senator(s) Jordan, Jackson (11th), To: Drug Policy Thomas SENATE BILL NO. 2278 1 AN ACT TO AMEND SECTION 41-29-113, MISSISSIPPI CODE OF 1972, 2 TO INCLUDE ISOTONITAZENE, FLUALPRAZOLAM, FLUBROMAZEPAM, 3 FLUBROMAZOLAM AND CLONAZOLAM TO SCHEDULE I BECAUSE THESE DRUGS 4 HAVE NO LEGITIMATE MEDICAL USE AND HAVE HIGH POTENCY WITH GREAT 5 POTENTIAL TO CAUSE HARM; TO AMEND SECTION 41-29-115, MISSISSIPPI 6 CODE OF 1972, TO REVISE THE CHEMICAL NAME OF THIAFENTANIL; TO 7 AMEND SECTION 41-29-119, MISSISSIPPI CODE OF 1972, TO INCLUDE 8 BREXANOLONE AND SOLRIAMFETOL AS SCHEDULE IV CONTROLLED SUBSTANCES 9 BECAUSE THE FEDERAL DRUG ADMINISTRATION RECENTLY APPROVED THESE 10 DRUGS FOR MEDICAL USE; AND FOR RELATED PURPOSES. 11 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI: 12 SECTION 1. Section 41-29-113, Mississippi Code of 1972, is 13 amended as follows: 14 41-29-113. 15 SCHEDULE I 16 (a) Schedule I consists of the drugs and other substances, 17 by whatever official name, common or usual name, chemical name, or 18 brand name designated, that is listed in this section. 19 (b) Opiates. Unless specifically excepted or unless listed 20 in another schedule, any of the following opiates, including their 21 isomers, esters, ethers, salts and salts of isomers, esters and S. B. No. 2278 *SS26/R204.1* ~ OFFICIAL ~ G1/2 21/SS26/R204.1 PAGE 1 (ens\tb) 22 ethers, whenever the existence of these isomers, esters, ethers 23 and salts is possible within the specific chemical designation: 24 (1) Acetyl-alpha-methylfentanyl; 25 (2) Acetyl Fentanyl 26 N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide; 27 (3) AH-7921 (3,4-dichloro-N-[(1-dimethylamino) 28 cyclohexylmethyl]benzamide); 29 (4) Acetylmethadol; 30 (5) Allylprodine; 31 (6) Alphacetylmethadol, except levo-alphacetylmethadol 32 (levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM); 33 (7) Alphameprodine; 34 (8) Alphamethadol; 35 (9) Alpha-methylfentanyl; 36 (10) Alpha-methylthiofentanyl; 37 (11) Benzethidine; 38 (12) Betacetylmethadol; 39 (13) Beta-hydroxyfentanyl; 40 (14) Beta-hydroxy-3-methylfentanyl; 41 (15) Betameprodine; 42 (16) Betamethadol; 43 (17) Betaprodine; 44 (18) Butyrl fentanyl 45 (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide); 46 (19) Clonitazene; S. B. No. 2278 *SS26/R204.1* ~ OFFICIAL ~ 21/SS26/R204.1 PAGE 2 (ens\tb) 47 (20) Dextromoramide; 48 (21) Diampromide; 49 (22) Diethylthiambutene; 50 (23) Difenoxin; 51 (24) Dimenoxadol; 52 (25) Dimepheptanol; 53 (26) Dimethylthiambutene; 54 (27) Dioxaphetyl butyrate; 55 (28) Dipipanone; 56 (29) Ethylmethylthiambutene; 57 (30) Etonitazene; 58 (31) Etoxeridine; 59 (32) Fentanyl-related substances, meaning any substance 60 not otherwise listed under another schedule and for which no 61 exemption or approval is in effect under Section 505 of the 62 Federal Food, Drug, and Cosmetic Act [21 USC 355] that is 63 structurally related to fentanyl by one or more of the following 64 modifications: 65 (A) Replacement of the phenyl portion of the 66 phenethyl group by any monocycle, whether or not further 67 substituted in or on the monocycle; 68 (B) Substitution in or on the phenethyl group with 69 alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or nitro 70 groups; S. B. No. 2278 *SS26/R204.1* ~ OFFICIAL ~ 21/SS26/R204.1 PAGE 3 (ens\tb) 71 (C) Substitution in or on the piperidine ring with 72 alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, 73 amino or nitro groups; 74 (D) Replacement of the aniline ring with any 75 aromatic monocycle whether or not further substituted in or on the 76 aromatic monocycle; and/or 77 (E) Replacement of the N-propionyl group by 78 another acyl group. 79 Fentanyl-related substances include, but are not limited to, 80 cyclopropyl fentanyl, 81 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide); 82 Furanyl-Fentanyl, 83 (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide); 84 valeryl fentanyl, 85 (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide); 86 para-fluorobutyryl fentanyl, 87 (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide); 88 para-methoxybutyryl fentanyl, 89 (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide); 90 para-chloroisobutyryl fentanyl, 91 (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide); 92 isobutyryl fentanyl, 93 (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide); S. B. No. 2278 *SS26/R204.1* ~ OFFICIAL ~ 21/SS26/R204.1 PAGE 4 (ens\tb) 94 cyclopentyl fentanyl, 95 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide); 96 and 97 ocfentanil, 98 (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetami 99 de); 100 (33) Furethidine; 101 (34) Hydroxypethidine; 102 (35) Isotonitazene (N,N-diethyl-2-(2-(4 103 isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine); 104 ( * * *36) Ketobemidone (including the optical and 105 geometric isomers); 106 ( * * *37) Levomoramide; 107 ( * * *38) Levophenacylmorphan; 108 ( * * *39) 3-methylfentanyl; 109 ( * * *40) 3-methylthiofentanyl; 110 ( * * *41) Morpheridine; 111 ( * * *42) MPPP 112 (1-methyl-4-phenyl-4-propionoxypiperidine); 113 ( * * *43) 114 N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylprop 115 ionamide, its isomers, esters, ethers, salts and salts of isomers, 116 esters and ethers (other names: beta-hydroxythiofentanyl); 117 ( * * *44) Noracymethadol; 118 ( * * *45) Norlevorphanol; S. B. No. 2278 *SS26/R204.1* ~ OFFICIAL ~ 21/SS26/R204.1 PAGE 5 (ens\tb) 119 ( * * *46) Normethadone; 120 ( * * *47) Norpipanone; 121 ( * * *48) Para-fluorofentanyl; 122 ( * * *49) PEPAP 123 (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine); 124 ( * * *50) Phenadoxone; 125 ( * * *51) Phenampromide; 126 ( * * *52) Phenomorphan; 127 ( * * *53) Phenoperidine; 128 ( * * *54) Piritramide; 129 ( * * *55) Proheptazine; 130 ( * * *56) Properidine; 131 ( * * *57) Propiram; 132 ( * * *58) Racemoramide; 133 ( * * *59) Thiofentanyl; 134 ( * * *60) Tilidine; 135 ( * * *61) Trimeperidine; 136 ( * * *62) U-47700, 137 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide. 138 (c) Opium derivatives. Unless specifically excepted or 139 unless listed in another schedule, any of the following opium 140 derivatives, their salts, isomers and salts of isomers, whenever 141 the existence of these salts, isomers and salts of isomers is 142 possible within the specific chemical designation: 143 (1) Acetorphine; S. B. No. 2278 *SS26/R204.1* ~ OFFICIAL ~ 21/SS26/R204.1 PAGE 6 (ens\tb) 144 (2) Acetyldihydrocodeine; 145 (3) Benzylmorphine; 146 (4) Codeine methylbromide; 147 (5) Codeine-N-Oxide; 148 (6) Cyprenorphine; 149 (7) Desomorphine; 150 (8) Dihydromorphine; 151 (9) Drotebanol; 152 (10) Etorphine (except hydrochloride salt); 153 (11) Heroin; 154 (12) Hydromorphinol; 155 (13) Methyldesorphine; 156 (14) Methyldihydromorphine; 157 (15) Monoacetylmorphine; 158 (16) Morphine methylbromide; 159 (17) Morphine methylsulfonate; 160 (18) Morphine-N-Oxide; 161 (19) Myrophine; 162 (20) Nicocodeine; 163 (21) Nicomorphine; 164 (22) Normorphine; 165 (23) Pholcodine; 166 (24) Thebacon. 167 (d) Hallucinogenic substances. Unless specifically excepted 168 or unless listed in another schedule, any material, compound, S. B. No. 2278 *SS26/R204.1* ~ OFFICIAL ~ 21/SS26/R204.1 PAGE 7 (ens\tb) 169 mixture or preparation which contains any quantity of the 170 following substances, their salts, isomers (whether optical, 171 positional, or geometric) and salts of isomers, whenever the 172 existence of these salts, isomers and salts of isomers is possible 173 within the specific chemical designation: 174 (1) Alpha-ethyltryptamine; 175 (2) 4-bromo-2,5-dimethoxy-amphetamine; 176 (3) 4-bromo-2,5-dimethoxyphenethylamine; 177 (4) 2,5-dimethoxyamphetamine; 178 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET); 179 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine 180 (2C-T-7); 181 (7) 4-methoxyamphetamine; 182 (8) 5-methoxy-3,4-methylenedioxy-amphetamine; 183 (9) 4-methyl-2,5-dimethoxy-amphetamine; 184 (10) 3,4-methylenedioxy amphetamine; 185 (11) 3,4-methylenedioxymethamphetamine (MDMA); 186 (12) 3,4-methylenedioxy-N-ethylamphetamine (also known 187 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl 188 MDA, MDE, MDEA); 189 (13) N-hydroxy-3,4-methylenedioxyamphetamine (also 190 known as N-hydroxy MDA, N-OHMDA, and 191 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine); 192 (14) 3,4,5-trimethoxy amphetamine; 193 (15) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT); S. B. No. 2278 *SS26/R204.1* ~ OFFICIAL ~ 21/SS26/R204.1 PAGE 8 (ens\tb) 194 (16) Alpha-methyltryptamine (also known as AMT); 195 (17) Bufotenine; 196 (18) Diethyltryptamine; 197 (19) Dimethyltryptamine; 198 (20) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT); 199 (21) Ibogaine; 200 (22) Lysergic acid diethylamide (LSD); 201 (23) (A) Marijuana (Hemp as defined and regulated 202 under Sections 69-25-201 through 69-25-221 and Cannabidiol 203 contained in a legend drug product approved by the Federal Food 204 and Drug Administration or obtained under Section 41-29-136 are 205 exempt under Schedule I); 206 (B) Hashish; 207 (24) Mescaline; 208 (25) Parahexyl; 209 (26) Peyote; 210 (27) N-ethyl-3-piperidyl benzilate; 211 (28) N-methyl-3-piperidyl benzilate; 212 (29) Psilocybin; 213 (30) Psilocyn; 214 (31) Tetrahydrocannabinols, meaning 215 tetrahydrocannabinols contained in a plant of the genus Cannabis 216 (cannabis plant), as well as the synthetic equivalents of the 217 substances contained in the cannabis plant, or in the resinous 218 extractives of such plant, and/or synthetic
Load more

Recommended publications
  • DART-MS/MS Screening for the Determination of 1,3- Dimethylamylamine and Undeclared Stimulants in Seized Dietary Supplements from Brazil
    Forensic Chemistry 8 (2018) 134–145 Contents lists available at ScienceDirect Forensic Chemistry journal homepage: www.elsevier.com/locate/forc DART-MS/MS screening for the determination of 1,3- dimethylamylamine and undeclared stimulants in seized dietary supplements from Brazil Maíra Kerpel dos Santos a, Emily Gleco b, J. Tyler Davidson b, Glen P. Jackson b, Renata Pereira Limberger a, ⇑ Luis E. Arroyo b, a Graduate Program of Pharmaceutical Sciences, Faculty of Pharmacy, Federal University of Rio Grande do Sul, Brazil b Department of Forensic & Investigative Science, West Virginia University, USA article info abstract Article history: 1,3-dimethylamylamine (DMAA) is an alkylamine with stimulating properties that has been used pre- Received 15 December 2017 dominantly as an additive in dietary supplements. DMAA is mostly consumed by professional athletes, Received in revised form 14 March 2018 and several doping cases reported since 2008 led to its prohibition by the World Anti-Doping Agency Accepted 18 March 2018 (WADA) in 2010. Adverse effects have indicated DMAA toxicity, and there is few data regarding its safety, Available online 22 March 2018 so it was banned by regulatory agencies from Brazil and the United States. Ambient ionization methods such as Direct Analysis in Real Time Tandem Mass Spectrometry (DART-MS/MS) are an alternative for Keywords: dietary supplements analysis, because they enable the analysis of samples at atmospheric pressure in 1,3-dimethylamylamine a very short time and with only minimal sample preparation. Therefore, the aim of this work was to DART-MS/MS Dietary supplements develop a methodology by DART-MS/MS to detect the presence of DMAA, ephedrine, synephrine, caffeine, Stimulants sibutramine, and methylphenidate in 108 dietary supplements seized by the Brazilian Federal Police Adulterants (BFP).
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Sibutramine Hydrochloride Monohydrate) Capsule CS-IV
    MERIDIA - sibutramine hydrochloride capsule ---------- MERIDIA® (sibutramine hydrochloride monohydrate) Capsule CS-IV DESCRIPTION MERIDIA® (sibutramine hydrochloride monohydrate) is an orally administered agent for the treatment of obesity. Chemically, the active ingredient is a racemic mixture of the (+) and (-) enantiomers of cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, hydrochloride, monohydrate, and has an empirical formula of C17H29Cl2NO. Its molecular weight is 334.33. The structural formula is shown below: Sibutramine hydrochloride monohydrate is a white to cream crystalline powder with a solubility of 2.9 mg/mL in pH 5.2 water. Its octanol: water partition coefficient is 30.9 at pH 5.0. Each MERIDIA capsule contains 5 mg, 10 mg, and 15 mg of sibutramine hydrochloride monohydrate. It also contains as inactive ingredients: lactose monohydrate, NF; microcrystalline cellulose, NF; colloidal silicon dioxide, NF; and magnesium stearate, NF in a hard-gelatin capsule [which contains titanium dioxide, USP; gelatin; FD&C Blue No. 2 (5- and 10-mg capsules only); D&C Yellow No. 10 (5- and 15-mg capsules only), and other inactive ingredients]. CLINICAL PHARMACOLOGY Mode of Action Sibutramine produces its therapeutic effects by norepinephrine, serotonin and dopamine reuptake inhibition. Sibutramine and its major pharmacologically active metabolites (M1 and M2) do not act via release of monoamines. Pharmacodynamics Sibutramine exerts its pharmacological actions predominantly via its secondary (M1) and primary (M2) amine metabolites. The parent compound, sibutramine, is a potent inhibitor of serotonin (5- hydroxytryptamine, 5-HT) and norepinephrine reuptake in vivo, but not in vitro. However, metabolites M1 and M2 inhibit the reuptake of these neurotransmitters both in vitro and in vivo.
    [Show full text]
  • CRITERIA for DRUG COVERAGE Solriamfetol (Sunosi)
    Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE Solriamfetol (Sunosi) Notes: * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation Initiation (new start) criteria: Non-formulary solriamfetol (Sunosi) will be covered on the prescription drug benefit for 12 months when the following criteria are met: • Prescribed by a Sleep Specialist • Prescribed for the treatment of excessive daytime sleepiness due to narcolepsy OR excessive daytime sleepiness due to obstructive sleep apnea (OSA) • Patient is 18 years of age or older • Patient has failed a trial of, or patient has an allergy or intolerance* to: o Modafinil or armodafinil AND o A stimulant medication (ie methylphenidate, dextroamphetamine, amphetamine salt combination, etc.) • OSA only: patient is currently treated for OSA [i.e. use of CPAP, or use of oral appliances (eg mandibular advancement device, tongue retaining devices), or had past OSA surgery] Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-formulary solriamfetol (Sunosi) will be covered on the prescription drug benefit for 24 months when the following criteria are met: • See above New Start criteria Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary solriamfetol (Sunosi) will be covered on the prescription drug benefit for 12 months when the
    [Show full text]
  • Short-Term Difference in Mood with Sibutramine Versus Placebo in Obese Patients with and Without Depression
    RESEARCH ARTICLE Short-term difference in mood with sibutramine versus placebo in obese patients with and without depression Kristina Elfhag† & Background: Sibutramine is an anti-obesity satiety-enhancing drug which elicits its effect Stephan Rössner by inhibiting the reuptake of serotonin and noradrenalin. Objective: The aim of †Author for correspondence this study was to test the short-term effect on mood with sibutramine versus placebo in Karolinska University Hospital, Obesity Unit, M73, obese patients with and without depressive features. Materials & methods: The SE-141 86 Stockholm, participants consisted of 36 obese patients with a mean body mass index of 39 kg/m2. Sweden Depressive features were measured with the Comprehensive Psychopathological Rating Tel.: +46 858 582 478 [email protected] Scale (CPRS). Sibutramine (15 mg) and placebo were administered daily in a cross-over design over 14-day periods. At baseline, 19 (53%) patients demonstrated depressive features. Results: A significant short-term difference, implying lower mood with sibutramine versus placebo, was observed for depressed patients, in particular, in the CPRS subscale for anxiety. This result persisted as statistically significant also when removing an item on increased sleeping difficulties in the CPRS anxiety scale. Sleeping difficulties, which are common side effects of anti-obesity drugs, were also greater with sibutramine in depressed patients. No differences were found in the nondepressed population. Conclusion: Patients with depressive features can be more susceptible to experiencing a relatively higher initial discomfort with sibutramine compared with placebo at onset of treatment. Sibutramine is an anti-obesity drug which pri- improvements in sibutramine treatment have marily enhances satiety through a process of been reported in an additional study of obese serotonin and noradrenalin reuptake inhibition binge eating patents and in a general clinical [1].
    [Show full text]
  • Phenylmorpholines and Analogues Thereof Phenylmorpholine Und Analoge Davon Phenylmorpholines Et Analogues De Celles-Ci
    (19) TZZ __T (11) EP 2 571 858 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 265/30 (2006.01) A61K 31/5375 (2006.01) 20.06.2018 Bulletin 2018/25 A61P 25/24 (2006.01) A61P 25/16 (2006.01) A61P 25/18 (2006.01) (21) Application number: 11723158.9 (86) International application number: (22) Date of filing: 20.05.2011 PCT/US2011/037361 (87) International publication number: WO 2011/146850 (24.11.2011 Gazette 2011/47) (54) PHENYLMORPHOLINES AND ANALOGUES THEREOF PHENYLMORPHOLINE UND ANALOGE DAVON PHENYLMORPHOLINES ET ANALOGUES DE CELLES-CI (84) Designated Contracting States: • DECKER, Ann Marie AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Durham, North Carolina 27713 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Hoeger, Stellrecht & Partner Patentanwälte mbB (30) Priority: 21.05.2010 US 347259 P Uhlandstrasse 14c 70182 Stuttgart (DE) (43) Date of publication of application: 27.03.2013 Bulletin 2013/13 (56) References cited: WO-A1-2004/052372 WO-A1-2008/026046 (73) Proprietors: WO-A1-2008/087512 DE-B- 1 135 464 • Research Triangle Institute FR-A- 1 397 563 GB-A- 883 220 Research Triangle Park, North Carolina 27709 GB-A- 899 386 US-A1- 2005 267 096 (US) • United States of America, as represented by • R.A. GLENNON ET AL.: "Beta-Oxygenated The Secretary, Department of Health and Human Analogues of the 5-HT2A Serotonin Receptor Services Agonist Bethesda, Maryland 20892-7660 (US) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopro pane", JOURNAL OF MEDICINAL CHEMISTRY, (72) Inventors: vol.
    [Show full text]
  • 124.210 Schedule IV — Substances Included. 1
    1 CONTROLLED SUBSTANCES, §124.210 124.210 Schedule IV — substances included. 1. Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: a. Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. b. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- propionoxybutane). c. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 3. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a. Alprazolam. b. Barbital. c. Bromazepam. d. Camazepam. e. Carisoprodol. f. Chloral betaine. g. Chloral hydrate. h. Chlordiazepoxide. i. Clobazam. j. Clonazepam. k. Clorazepate. l. Clotiazepam. m. Cloxazolam. n. Delorazepam. o. Diazepam. p. Dichloralphenazone. q. Estazolam. r. Ethchlorvynol. s. Ethinamate. t. Ethyl Loflazepate. u. Fludiazepam. v. Flunitrazepam. w. Flurazepam. x. Halazepam. y. Haloxazolam. z. Ketazolam. aa. Loprazolam. ab. Lorazepam. ac. Lormetazepam. ad. Mebutamate. ae. Medazepam. af. Meprobamate. ag. Methohexital. ah. Methylphenobarbital (mephobarbital).
    [Show full text]
  • BOARD MEETING AGENDA Meeting Location: Portland State Office Building 800 NE Oregon Street, Portland, OR 97232 June 6-7, 2018 Updated 6.4.18
    Oregon Board of Pharmacy BOARD MEETING AGENDA Meeting Location: Portland State Office Building 800 NE Oregon Street, Portland, OR 97232 June 6-7, 2018 Updated 6.4.18 The mission of the Oregon State Board of Pharmacy is to promote, preserve and protect the public health, safety and welfare by ensuring high standards in the practice of pharmacy and by regulating the quality, manufacture, sale and distribution of drugs. Wednesday, June 6, 2018 @ 8:30AM – Conference Rm A Thursday, June 7, 2018 @ 8:30AM – Conference Room A ≈ If special accommodations are needed for you to attend or participate in this Board Meeting, please contact Loretta Glenn at: (971) 673-0001. ≈ WEDNESDAY, JUNE 6, 2018 I. 8:30AM OPEN SESSION, Penny Reher, R.Ph, Presiding A. Roll Call B. Agenda Review and Approval Action Necessary II. Contested Case Deliberation pursuant to ORS 192.690(1) - Not Open to the Public III. EXECUTIVE SESSION – NOT OPEN TO THE PUBLIC, pursuant to ORS 676.175, ORS 192.660 (1) (2) (f) (k). A. Items for Consideration and Discussion: 1. Deliberation on Disciplinary Cases and Investigations 2. Personal Appearances 3. Deficiency Notifications 4. Case Review B. Employee Performance Review pursuant to ORS 192.660(2)(i). IV. OPEN SESSION - PUBLIC MAY ATTEND - At the conclusion of Executive Session, the Board may convene Open Session to begin some of the following scheduled agenda items - time permitting at approximately 3:30PM. V. Approve Consent Agenda* Action Necessary *Items listed under the consent agenda are considered to be routine agency matters and will be approved by a single motion of the Board without separate discussion.
    [Show full text]
  • Prezentace Aplikace Powerpoint
    P.719 NAPHYRONE – PHARMACOKINETICS AND BEHAVIOURAL PROFILE IN WISTAR RAT Olejíková Lucie, Štefková Kristýa, Šíchová Klára, Dada Hyek, Lhotková Eva, Piterová Nikola, Páleíček Toáš National Institute of Mental Health, Klecany, Czech Republic NAPHYRONE METHODS Naphyrone (naphthylpyrovalerone, O-2482, Energy 1), from the Naphyrone was administered subcutaneously to Wistar rats in a single dose of 5 cathinones group, is a drug derived from pyrovalerone that acts as a triple mg/kg, 10 mg/kg and 20 mg/kg. Open field test was performed in an empty black reuptake inhibitor, producing stimulant effects similar to cocaine, MDMA square arena (68 c × 68 c × 30 c). Rats were placed individually into the center of or amphetamines and has been reported as a novel psychoactive the arena 5 or 40 i after the drug administration (testing-onset) and their behavior was recorded for 30 i. Examined parameters were trajectory length, its spatial substance (NPS). characteristic (thigmotaxis and time spent in the center of the arena). Further the prepulse inhibition (PPI) of acoustic startle reaction (ASR) were determined in this study. Pharmacokinetic profile was analyzed using gas chromatography-mass spectrometry (GCMS). To simulate effects of crowded conditions, body temperature was monitored in animals housed in groups versus individually. Data were analyzed using factorial Analysis of Variance and independent t-tests. RESULTS LOCOMOTION PREPULSE INHIBITION OF ACOUSTIC STARTLE REACTION lenght (m) Trajectory Fig. 1: The effect of naphyrone on total locomotion 15 and 60 min after administration. Data are Fig. 3: The effect of naphyrone on prepulse inhibition (PPI) of acoustic startle reaction (ASR). PPI presented as mean±SEM.
    [Show full text]
  • Introduced B.,Byhansen, 16
    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Expansion of a Cheminformatic Database of Spectral Data for Forensic Chemists and Toxicologists
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Expansion of a Cheminformatic Database of Spectral Data for Forensic Chemists and Toxicologists Author(s): Peter Stout, Katherine Moore, Megan Grabenauer, Jeri Ropero-Miller Document No.: 241444 Date Received: March 2013 Award Number: 2010-DN-BX-K177 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant report available electronically. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Award Number: 2010-DN-BX-K177 July 16, 2012 Expansion of a Cheminformatic Database of Spectral Data for Forensic Chemists and Toxicologists Final Report Authors: Peter Stout Katherine Moore Megan Grabenauer Jeri Ropero-Miller This document is a research report submitted to the U.S. Department of Justice. This report has not been published by the Department. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Expansion of a Cheminformatic Database of Spectral Data for Forensic Chemists and Toxicologists Table of Contents Abstract ........................................................................................................................................... 1 Executive Summary .......................................................................................................................
    [Show full text]